AKTS · Company research
Aktis Oncology, Inc. Common stock (AKTS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| 93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP - MarketBeat | 93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP MarketBeat | View source ↗ | MarketBeat | Oct 10, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology (NASDAQ:AKTS) Stock Keeps "Outperform" Rating at Wedbush - MarketBeat | Aktis Oncology (NASDAQ:AKTS) Stock Keeps "Outperform" Rating at Wedbush MarketBeat | View source ↗ | MarketBeat | Oct 6, 2026 | neutral | 0 | 0.6 |
| A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. - Stock Titan | A cancer drug will be tested in lung cancer; its prostate-cancer trial is enrolling. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan | After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6% - Here's What Happened - MarketBeat | Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6% - Here's What Happened MarketBeat | View source ↗ | MarketBeat | Sep 23, 2026 | neutral | 0 | 0.6 |
| $AKTS stock is down 10% today. Here's what we see in our data. | AKTS Stock News - Quiver Quantitative | $AKTS stock is down 10% today. Here's what we see in our data. | AKTS Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 8, 2026 | neutral | 0 | 0.6 |
| Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - Simply Wall Street | Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? Simply Wall Street | View source ↗ | Simply Wall Street | Jul 24, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com | Aktis Oncology director Ken Herrmann sells $119,274 in stock Investing.com | View source ↗ | Investing.com | Jul 21, 2026 | neutral | 0 | 0.6 |
| $AKTS stock is down 12% today. Here's what we see in our data. - Quiver Quantitative | $AKTS stock is down 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 13, 2026 | neutral | 0 | 0.6 |
| AKTS Forecast — Price Target — Prediction for 2027 - TradingView | AKTS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) - Seeking Alpha | Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 16, 2026 | neutral | 0 | 0.6 |
| A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance | A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound Yahoo Finance | View source ↗ | Yahoo Finance | May 25, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump - Yahoo Finance | Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump Yahoo Finance | View source ↗ | Yahoo Finance | Apr 26, 2026 | neutral | 0 | 0.6 |
| Should I buy Aktis Oncology, Inc. (AKTS) - Zacks Investment Research | Should I buy Aktis Oncology, Inc. (AKTS) Zacks Investment Research | View source ↗ | Zacks Investment Research | Apr 17, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology, Inc. Common stock (AKTS) Stock Price: Oct 8 Close $17.74 - Gotrade | Aktis Oncology, Inc. Common stock (AKTS) Stock Price: Oct 8 Close $17.74 Gotrade | View source ↗ | Gotrade | Jan 10, 2026 | neutral | 0 | 0.6 |
| Aktis Oncology (Nasdaq:AKTS) - Stock Analysis - Simply Wall Street | Aktis Oncology (Nasdaq:AKTS) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Jan 10, 2026 | neutral | 0 | 0.6 |
| Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals - MedCity News | Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals MedCity News | View source ↗ | MedCity News | Jan 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.